You just read:

Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

News provided by

Therapix Biosciences Ltd.

Dec 02, 2019, 09:20 ET